MOVENTIG INFORMATION FOR HEALTHCARE PROFESSIONALS

As a healthcare professional, you will be familiar with the fact that opioids prescribed for pain relief often cause constipation as a side-effect. This is known as opioid-induced constipation, or OIC. It has been shown that most users of opioids will experience OIC.1

Constipation is caused by both weak opioids (e.g. tramadol, codeine) and strong opioids (e.g. morphine, oxycodone) to a similar degree.2

Laxatives are the first-line treatment in all forms of constipation, including OIC. However, many patients suffering from OIC do not respond adequately to laxative therapy and require alternative treatment to manage their condition.3

Click here to watch a video about how OIC differs from other forms of constipation, why laxatives don’t always provide adequate relief and how MOVENTIG can provide a treatment option for some patients.

video-placeholder

The information on this website is intended to help you decide whether MOVENTIG is an appropriate treatment option for your patients suffering from OIC who have not responded adequately to laxatives*.

You will find information on efficacy, tolerability and how to take MOVENTIG. You can also access accredited CPD modules for various medical specialties as well as in-depth e-learning modules on OIC and MOVENTIG itself. There are expert opinion videos to watch and a summary of official guidelines on the management of OIC.

*MOVENTIG is indicated for the treatment of OIC in adult patients who have had an inadequate response to laxatives. Laxative inadequate responders (LIR) are defined as patients who, in the two weeks prior to the first study visit, had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.4